UK deal over inclisiran

Editorial expresses concern over recent announcement by UK government of an “innovative and ground-breaking collaboration” with Novartis to launch a clinical trial of inclisiran, a new cholesterol lowering drug, highlighting funding decisions must be based on unbiased evaluation.

British Medical Journal